Virpax Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Net Income	-12.07	-15.19	-21.65	-12.06	-4.34	Upgrade
Stock-Based Compensation	0.13	0.54	0.75	0.97	1.48	Upgrade
Other Operating Activities	-	-	-	-0.06	0.15	Upgrade
Change in Accounts Payable	0.78	0.6	-0.99	-0.69	1.34	Upgrade
Change in Other Net Operating Assets	-5.56	4.19	4.05	-2.71	-0.01	Upgrade
Operating Cash Flow	-16.71	-9.85	-17.85	-14.54	-1.38	Upgrade
Long-Term Debt Issued	-	-	-	0.1	0.07	Upgrade
Long-Term Debt Repaid	-	-	-	-1.6	-	Upgrade
Net Debt Issued (Repaid)	-	-	-	-1.5	0.07	Upgrade
Issuance of Common Stock	9.08	-	-	58.02	1.38	Upgrade
Other Financing Activities	-	-	-	-5.19	-0.05	Upgrade
Financing Cash Flow	9.08	-	-	51.33	1.4	Upgrade
Net Cash Flow	-7.63	-9.85	-17.85	36.79	0.01	Upgrade
Cash Interest Paid	-	-	-	0.36	-	Upgrade
Levered Free Cash Flow	-12.26	-5.25	-7.66	-10.34	0.35	Upgrade
Unlevered Free Cash Flow	-12.2	-5.25	-7.66	-10.28	0.44	Upgrade
Change in Net Working Capital	4.78	-4.79	-3.06	3.74	-1.59	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.